Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Clonazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 5/20 | 1.00 |
| ▸ | GABRA5 known ✓ | P31644 | 5/20 | 1.00 |
| ▸ | GABRA3 known ✓ | P34903 | 5/20 | 1.00 |
| ▸ | GABRA2 known ✓ | P47869 | 5/20 | 1.00 |
| ▸ | GABRB2 known ✓ | P47870 | 4/20 | 1.00 |
| ▸ | GABRG2 known ✓ | P18507 | 4/20 | 1.00 |
| ▸ | GABRB3 known ✓ | P28472 | 4/20 | 1.00 |
| ▸ | GABRP known ✓ | O00591 | 3/20 | 1.00 |
| ▸ | GABRD known ✓ | O14764 | 3/20 | 1.00 |
| ▸ | GABRB1 known ✓ | P18505 | 3/20 | 1.00 |
| ▸ | GABRA4 known ✓ | P48169 | 3/20 | 1.00 |
| ▸ | GABRE known ✓ | P78334 | 3/20 | 1.00 |
| ▸ | GABRA6 known ✓ | Q16445 | 3/20 | 1.00 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 3/20 | 1.00 |
| ▸ | GABRG3 known ✓ | Q99928 | 3/20 | 1.00 |
| ▸ | GABRQ known ✓ | Q9UN88 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clonazepam SCHEMBL38899 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL13747803 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL13746712 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL29369721 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL29361251 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL29743048 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL28390843 | 0.99 | GABRA1 (0.98) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL31321724 | 0.99 | GABRA1 (0.98) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL9834407 | 0.99 | GABRA1 (0.98) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL20771795 | 0.98 | GABRA1 (0.96) | GABRA1GABRA5GABRA3GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906208-A1 | THERAPEUTIC TREATMENT | Sears, Douglas (US) | 2015-08-19 | — | — | EP | disclosed |
| EP-2758053-A1 | SODIUM CHANNEL BLOCKERS REDUCE GLUCAGON SECRETION | Gilead Sciences, Inc. (US) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013043925-A1 | SODIUM CHANNEL BLOCKERS REDUCE GLUCAGON SECRETION | GILEAD SCIENCES, INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| CN-101398414-B | Method for qualitatively screening 242 kinds of compounds by liquid phase chromatography-mass spectra at the same times | CRIMINAL INVEST DEPT OF SHANGHAI POLICE STATION | 2011-07-20 | — | — | CN | disclosed |
| CN-101398414-A | Method for qualitatively screening 242 kinds of compounds by liquid phase chromatography-mass spectra at the same times | CRIMINAL INVEST GENERAL UNIT O (CN) | 2009-04-01 | — | — | CN | disclosed |
| CN-1960781-A | Therapeutic combination for treatment of alzheimers disease | WARNER LAMBERT CO (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1737539-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1696959-A2 | MELATONIN COMBINATION THERAPY FOR IMPROVING SLEEP QUALITY | Sepracor, Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| EP-1691811-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | Sepracor, Inc. (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005112911-A2 | COMPOSITIONS AND METHODS FOR TREATING MYELIN DEFICIENCY DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005099823-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |
| WO-2005063297-A2 | MELATONIN COMBINATION THERAPY FOR IMPROVING SLEEP QUALITY | SEPRACOR INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005063248-A1 | MODAFINIL COMBINATION THERAPY FOR IMPROVING SLEEP QUALITY | SEPRACOR INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005060968-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2005-07-07 | — | — | WO | disclosed |